Abstracts tagged "Lupus nephritis"

Abstract Number: 0769 • ACR Convergence 2021
Renal Outcomes in 1528 Childhood-onset Systemic Lupus Erythematosus Patients: A Brazilian Multicenter Study
Ana Paula Sakamoto¹, Clovis Silva², Aline Islabão³, Glaucia Novak², Beatriz Molinari², Rosa Pereira⁴, Claudia Saad-Magalhães⁵, Gleice Clemente⁶, Daniela Petry Pioto⁷, Nadia Aikawa⁴, Ana Pita², Vitor Trindade², Simone Appenzeller⁸, Luciana Carvalho⁹, Carlos Rabelo-Junior¹⁰, Adriana Fonseca¹¹, Flavio Sztajnbok¹², Maria Santos¹³, Blanca Elena Rios Gomes Bica¹⁴, Evaldo Sena¹⁵, Ana Moraes¹⁶, Melissa Fraga⁶, Teresa Robazzi¹⁷, Paulo Spelling¹⁸, Iloite Scheibel¹⁹, Andre Cavalcanti²⁰, Erica Matos²¹, Luciano Guimarães²², Flavia Santos²³, Licia Maria Henrique Mota²⁴, Eloisa Bonfá⁴ and Maria Terreri²⁵, ¹Federal University of So Paulo (UNIFESP), São Paulo, Brazil, ²Pediatric Rheumatology Unit, Children’s Institute, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil, ³Pediatric Rheumatology Unit, Hospital da Criança de Brasília Jose Alencar, Brasilia, DF, Brazil, ⁴Hospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ⁵Pediatric Rheumatology Division, São Paulo State University (UNESP) – Faculdade de Medicina de Botucatu, Botucatu, Botucatu, Brazil, ⁶Universidade Federal de São Paulo, São Paulo, Brazil, ⁷Pediatric Rheumatology Unit, Universidade Federal de São Paulo, São Paulo, SP, Brazil, ⁸Hospital das Clínicas da Universidade Estadual de Campinas, Campinas, Brazil, ⁹Pediatric Rheumatology Unit, Ribeirão Preto Medical School – University of São Paulo, Ribeirão Preto, SP, Brazil, ¹⁰Pediatric Rheumatology Unit, Hospital Geral de Fortaleza, Fortaleza, CE, Brazil, ¹¹Pediatric Rheumatology Unit, Rio de Janeiro Federal University (IPPMG-UFRJ), Rio de Janeiro, RJ, Brazil, ¹²UFRJ/UERJ, Rio de Janeiro, Brazil, ¹³Pediatric Rheumatology Unit, Irmandade da Santa Casa de Misericórdia de São Paulo, São Paulo, SP, Brazil, ¹⁴Faculdade de Medicina, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil, ¹⁵Pediatric Rheumatology Unit, Lauro Vanderley University Hospital, João Pessoa, PB, Brazil, ¹⁶Pediatric Rheumatology Unit, Federal University of Pará, Belém, PA, Brazil, ¹⁷Pediatric Rheumatology Unit, Federal University of Bahia, Salvador, BA, Brazil, ¹⁸Pediatric Rheumatology Unit, Hospital Evangélico de Curitiba, Curitiba, PR, Brazil, ¹⁹Pediatric Rheumatology Unit, Hospital Criança Conceição, Porto Alegre, RS, Brazil, ²⁰Pediatric Rheumatology Unit, Federal University of Pernambuco, Recife, PE, Brazil, ²¹Pediatric Rheumatology Unit, Federal University of Mato Grosso do Sul, Campo Grande, MS, Brazil, ²²Pediatric Rheumatology Unit, University of Brasília, Brasilia, DF, Brazil, ²³Pediatric Rheumatology Unit, Federal University of Minas Gerais, Belo Horizonte, Belo Horizonte, MG, Brazil, ²⁴Universidade de Brasília, Brasilia, Brazil, ²⁵UNIFESP, São Paulo, Brazil
Background/Purpose: Lupus nephritis is a frequent manifestation in childhood-onset systemic lupus erythematosus (cSLE) and has a great potential for chronic kidney disease (CKD), requiring dialysis…
Abstract Number: 1460 • ACR Convergence 2021
Lupus Nephritis Renal Responses in Relation to Treatment and Demographics: Observations from a Multi-racial/ethnic Cohort of 159 Patients in the NYU Lupus Registry
Mayce Haj-Ali¹, Kristina Deonaraine², Alexis Engel³, Yingzhi Qian¹, Amit Saxena⁴, Peter Izmirly², Jill Buyon⁴ and H. Michael Belmont⁴, ¹NYU Grossman School of Medicine, New York, NY, ²New York University School of Medicine, New York, NY, ³NYU Langone Health, New Yok, NY, ⁴NYU School of Medicine, New York, NY
Background/Purpose: Lupus nephritis (LN) disproportionately affects racial and ethnic populations. Contreras reported African-American (AA) and Hispanic patients had worse outcomes as compared to patients of…
Abstract Number: 1754 • ACR Convergence 2021
Effect of Belimumab on Autoantibodies, Complement, and B-Cell Subsets in Patients with Lupus Nephritis
Brad Rovin¹, Richard Furie², Ana Malvar³, Cynthia Aranow⁴, Jose M Pego-Reigosa⁵, Elena Zakharova⁶, Andreas Schwarting⁷, Angela Jones-Leone⁸, Anuradha Madan⁸, Jennifer Gilbride⁹, David Roth⁸, Yulia Green⁹ and André van Maurik¹⁰, ¹Ohio State University Wexner Medical Center, Columbus, OH, ²Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, ³Hospital Fernandez, Buenos Aires, Argentina, ⁴Feinstein Institutes for Medical Research, Manhasset, NY, ⁵Complexo Hospitalario Universitario de Vigo, Hospital Meixoeiro, Galicia Sur Health Research Institute, Rheumatology Department and IRIDIS (Investigation in Rheumatology and Immune-Mediated Diseases) Group, Vigo, Spain, ⁶Moscow City Clinical Hospital n.a. S.P. Botkin, Moscow, Russia, ⁷University Center of Autoimmunity, Mainz, Germany, ⁸GlaxoSmithKline, Collegeville, PA, ⁹GlaxoSmithKline, Brentford, United Kingdom, ¹⁰GlaxoSmithKline, Stevenage, Hertfordshire, United Kingdom
Background/Purpose: Lupus nephritis (LN) is a complication affecting ~40% of patients with systemic lupus erythematosus (SLE). Belimumab (BEL), an anti–B-lymphocyte stimulator therapy, was approved in…
Abstract Number: 0326 • ACR Convergence 2021
Apolipoprotein L1 (APOL1) in African-American SLE: Frequency and Clinical Associations
Michelle Petri¹, Romy Kallas², Jessica Li³, Laurence Magder⁴ and Daniel Goldman¹, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Lankenau Medical Center, Lankenau, PA, ³Johns Hopkins University, Baltimore, MD, ⁴University of Maryland, Baltimore, Baltimore, MD
Background/Purpose: The APOL1 gene is implicated in induction of TLR3 agonists and interferons as well as in autophagy. Two genetic variants, G1 (2 single nucleotide…
Abstract Number: 0784 • ACR Convergence 2021
Use of EuroLupus Cyclophosphamide Dosing for the Treatment of Lupus Nephritis in Childhood-Onset Systemic Lupus Erythematosus in North America
Laura Cannon¹, Scott Wenderfer², Laura Lewandowski³, Jennifer Cooper⁴, Beatrice Goilav⁵, Andrea Knight⁶, Aimee Hersh⁷, Stacy Ardoin⁸ and Rebecca Sadun¹, ¹Duke University, Durham, NC, ²Baylor College of Medicine, Houston, TX, ³NIAMS, NIH, Rockville, MD, ⁴University of Colorado/Children's Hospital Colorado, Denver, CO, ⁵Children's Hospital at Montefiore, Bronx, NY, ⁶Hospital for Sick Children, Toronto, ON, Canada, ⁷University of Utah, Salt Lake City, UT, ⁸Nationwide Children's Hospital, Columbus, OH
Background/Purpose: Childhood-onset systemic lupus erythematosus (cSLE) has higher rates of lupus nephritis (LN) than adult-onset SLE, often requiring intensive immunosuppression. This study examined North American…
Abstract Number: 1461 • ACR Convergence 2021
Belimumab Improves Renal Responses in Patients with or Without Steroid Pulses During Induction Therapy for Lupus Nephritis
Richard Furie¹, Frédéric Houssiau², Liz Lightstone³, Xueqing Yu⁴, Julia Weinmann-Menke⁵, Yoshiya Tanaka⁶, Angela Jones-Leone⁷, Tania Gonzalez-Rivera⁷, Jennifer Gilbride⁸, Anuradha Madan⁷, Yulia Green⁸ and David Roth⁷, ¹Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, ²Cliniques Universitaires Saint-Luc, UCLouvain, Brussels, Belgium, ³Department of Immunology and Inflammation, Imperial College, London, United Kingdom, ⁴Guangdong Provincial People’s Hospital and Guangdong Academy of Medical Sciences, Guangzhou, China (People's Republic), ⁵University Hospital Mainz, Mainz, Germany, ⁶University of Occupational and Environmental Health, Kitakyushu, Japan, ⁷GlaxoSmithKline, Collegeville, PA, ⁸GlaxoSmithKline, Brentford, United Kingdom
Background/Purpose: In the BLISS-LN trial (GSK Study BEL114054; NCT01639339), the administration of belimumab (BEL), a B-lymphocyte stimulator antagonist, resulted in improved renal outcomes in patients…
Abstract Number: 1756 • ACR Convergence 2021
Class V Systemic Lupus Erythematosus Nephritis Patients Are Undertreated and Face Similar Adverse Renal Outcomes as Class III/IV Patients
April Barnado and Alex Camai, Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Few studies have investigated treatment patterns and renal outcomes in class V systemic lupus erythematosus (SLE) nephritis patients compared to class III/IV patients. Prior…
Abstract Number: 0328 • ACR Convergence 2021
Natural Language Processing to Identify Lupus Nephritis Phenotype in Electronic Health Records
Yu Deng¹, Jennifer Pacheco¹, Anh Chung¹, Chengsheng Mao¹, Joshua Smith², juan zhao¹, Wei-Qi Wei², April Barnado³, Chunhua Weng⁴, Cong Liu⁴, Adam Gordon¹, Jingzhi Yu¹, Yacob Tedla¹, Abel Kho¹, Rosalind Ramsey-Goldman¹, Theresa Walunas¹ and Yuan Luo¹, ¹Northwestern University, Chicago, IL, ²Vanderbilt Universty Medical Center, Nashville, TN, ³Vanderbilt University Medical Center, Nashville, TN, ⁴Columbia University, New York, NY
Background/Purpose: Lupus nephritis (LN) is a major disease manifestation of Systemic lupus erythematosus (SLE) leading to organ damage and increased mortality. Accurately identifying lupus nephritis…
Abstract Number: 0874 • ACR Convergence 2021
Serum Galectin-9 and CXCL-10 but Not Their Urinary Levels Reflect Lupus Activity
Pankti Mehta, Pratibha Singh and Amita Aggarwal, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India
Background/Purpose: SLE is characterized by increased type I IFN signature in the blood and immune cells. Traditionally, type I IFN signature is measured by gene…
Abstract Number: 1482 • ACR Convergence 2021
LN Urinary Proteomics Reveals Common Biological Pathways Identified by Distinct Disease Measures
Paul Newcombe¹, Madhu Ramaswamy², Dominic Sinibaldi², Catharina Lindholm³, Frederick Jones¹, Ahmad Akhgar², Philip Brohawn², Raj Tummala² and Wendy White², ¹BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom, ²BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, ³BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden
Background/Purpose: LN is a severe consequence of SLE and there is a huge unmet need for discovery of urine protein biomarkers that provide non-invasive surrogates…
Abstract Number: 1766 • ACR Convergence 2021
Itolizumab-induced Modulation of Cell Surface CD6 Is a Pharmacodynamic Marker of Drug Activity in SLE Patients
Dalena Chu¹, Leslie Chinn², Jeanette Ampudia¹, Krishna Polu¹, Joel Rothman¹, Maple Fung³, Dolca Thomas⁴, Chaim Putterman⁵, Cherie Ng¹ and Stephen Connelly¹, ¹Equillium, Inc., La Jolla, CA, ²Equillium, Inc., South San Francisco, CA, ³Equillium, Inc., San Diego, CA, ⁴Equillium, Inc., Brooklyn, NY, ⁵Albert Einstein College of Medicine, Bronx, NY
Background/Purpose: Itolizumab (ITO) is a novel first-in-class monoclonal antibody (IgG1-k) specific for CD6, a co-stimulatory receptor that is highly expressed on T cells that plays…
Abstract Number: 0340 • ACR Convergence 2021
Urinary L-selectin Predicts Disease Activity and Histological Changes in Lupus Nephritis
Huihua Ding¹, Yiwei Shen¹, Min Dai¹, Chandra Mohan² and Nan Shen³, ¹Shanghai JiaoTong University School of Medicine, Shanghai, China (People's Republic), ²University of Houston, Houston, TX, ³Shanghai Jiang Tong University School of Medicine, Shanghai, China (People's Republic)
Background/Purpose: There remains unmet needs of non-invasive markers of disease activity, damage, prognosis, and treatment response in lupus nephritis patients. Here, we aim to validate…
Abstract Number: 0888 • ACR Convergence 2021
Disease Flares in Lupus Are Concordant with Ruminococcus Blautia Gnavus Blooms Within Unstable Gut Microbiota Communities
Doua Azzouz¹, Ze Chen¹, Zhi Li¹, Jing Deng¹, Peter Izmirly¹, David Fenyo¹, Jill Buyon¹, Alexander Alekseyenko² and Gregg Silverman¹, ¹NYU Grossman School of Medicine, New York, NY, ²Medical University of South Carolina, Charleston, SC
Background/Purpose: Systemic Lupus Erythematosus is the archetypic systemic autoimmune disease in which dysbiosis in the gut microbiome has been postulated to contribute to disease development…
Abstract Number: 1484 • ACR Convergence 2021
B Cell Intracellular IFNβ as a Unique Cellular Marker for the Development of Lupus Nephritis
Fatima Alduraibi¹, Huma Fatima¹, Winn Chatham², Hui-Chen Hsu¹ and John Mountz¹, ¹University of Alabama Birmingham, Birmingham, AL, ²University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Our laboratory previously demonstrated a strong association of B cell intracellular interferon beta (IFNβ) with the development of anti-Smith/ribonuclear protein (Sm/RNP), anti-DNA, and lupus…
Abstract Number: 1936 • ACR Convergence 2021
A Neutrophil Degranulation Signature Identifies Proliferative Lupus Nephritis
Andrea Fava¹, Jessica Li¹, Daniel Goldman², Brendan Antiochos¹, Jose Monroy-Trujillo¹, Derek Fine¹, Mohamed G. Atta¹, Jill Buyon³, Joel Guthridge⁴, Judith James⁴, Michelle Petri² and Accelerating Medicines Partership (AMP) RA/SLE Network⁵, ¹Johns Hopkins University, Baltimore, MD, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³NYU School of Medicine, New York, NY, ⁴Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵Brigham and Women's Hospital, Everett, MA
Background/Purpose: The identification of intrarenal pathological processes is key to develop better diagnostic and treatment strategies in lupus nephritis (LN). But the direct comprehensive study…